Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170000 | 0.85 | CRHR1 (0.43) | CRHR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6833888 | 0.78 | CRHR1 (0.45) | CRHR1MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL4168717 | 0.77 | CRHR1 (0.46) | CRHR1MEN1MAPTCYP2C9KMT2A | |
| SCHEMBL4175777 | 0.76 | RAB9A (0.50) | CRHR1MEN1MAPTKMT2AGAA | |
| SCHEMBL6689493 | 0.74 | CRHR1 (0.44) | CRHR1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL4180510 | 0.74 | KDR (0.46) | CRHR1MEN1CYP2C9KMT2AALDH1A1 | |
| SCHEMBL4173893 | 0.74 | CRHR1 (0.44) | CRHR1MAPTALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL4160444 | 0.73 | — | — | |
| SCHEMBL6691180 | 0.72 | CRHR1 (0.43) | CRHR1MEN1CYP2C9KMT2AALDH1A1 | |
| SCHEMBL4178920 | 0.71 | CRHR1 (0.40) | CRHR1MAPTCYP2C9ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105261-A1 | Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | GREENPHARMA (FR) | 2009-04-23 | — | — | US | claimed |
| US-20060106019-A1 | Novel substituted pyrazolo[1,5 a]-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | GREENPHARMA (FR) | 2006-05-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106019-A1 | Novel substituted pyrazolo[1,5 a]-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | PMP22, BDNF, GRIK5 | CRHR1 1700/4885MEN1 3393/4885MAPT 131/4885 |
| US-20090105261-A1 | Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | BDNF, NTRK2, NGF | CRHR1 107/4885MEN1 1687/4885MAPT 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.